TG Therapeutics Surpasses EPS and Revenue Estimates This Quarter

TG Therapeutics reported a strong fourth quarter, exceeding expectations with $108.2M in revenue and $0.15 EPS. The stock has surged nearly 27% week-to-date, driven by sales of Briumvi, and positive guidance adds bullish sentiment from investors.

Date: 08-03-2025

AI Rating: 8

Strong Earnings Performance
TG Therapeutics has demonstrated significant growth in both revenue and net income for the fourth quarter. The company reported revenues of approximately $108.2 million, which is more than double the $44 million reported in the same quarter of 2023. This bold increase indicates robust demand for TG Therapeutics’ only commercialized drug, Briumvi. Furthermore, the company reported a GAAP net income of $23.3 million for the quarter, a noteworthy reversal from the prior year’s loss of $14.4 million. This shows a strong turnaround in financial health, which is a key indicator for investors.

Exceeding Analyst Expectations
Both the revenue and earnings per share (EPS) of $0.15 exceeded analyst consensus estimates, which were less than $98 million in revenue and an EPS of $0.07. This strong performance is likely to create a positive sentiment towards the stock among investors, as exceeding expectations generally drives up stock prices.

Guidance and Future Potential
The company provided optimistic guidance projecting full-year 2024 revenue of around $540 million, predominantly from Briumvi sales in the U.S. This adds further positivity as it depicts the company's growth trajectory, which is crucial for long-term investors. Additionally, the drug’s continued expansion into foreign markets augments the optimism surrounding TG Therapeutics’ market position and growth potential.

Conclusion
Overall, the financial performance, guidance, and market potential from Briumvi positions TG Therapeutics favorably in the eyes of investors. The combination of robust sales growth and a solid earnings outlook makes it an attractive option for stakeholders looking for growth in the biotechnology sector.

Stocks: TGTX